Literature DB >> 26003469

Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Joseph L Kuti1, Rebecca S Pettit2, Natalie Neu3, Jeffrey J Cies4, Craig Lapin5, Marianne S Muhlebach6, Kimberly J Novak7, Sean T Nguyen8, Lisa Saiman3, David P Nicolau9.   

Abstract

The activity of ceftolozane/tazobactam was tested against 50 nonduplicate Pseudomonas aeruginosa from 18 cystic fibrosis children collected in 2012-2014. These isolates were multidrug resistant with susceptibility to meropenem, ceftazidime, and piperacillin/tazobactam of 46%, 58%, and 50%, respectively. Ceftolozane/tazobactam was the most active with MIC50, MIC90, and percent susceptibility of 2mg/L, 8 mg/L, and 86%.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic; Beta-lactam; Cystic fibrosis; Pseudomonas; Susceptibility

Mesh：

Substances：

Year:  2015        PMID： 26003469     DOI： 10.1016/j.diagmicrobio.2015.04.012

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  15 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Authors:  Patrick Grohs; Gary Taieb; Philippe Morand; Iheb Kaibi; Isabelle Podglajen; Marie Lavollay; Jean-Luc Mainardi; Fabrice Compain
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 3.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.

Authors:  Marguerite L Monogue; Rebecca S Pettit; Marianne Muhlebach; Jeffrey J Cies; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

Authors:  Jocelyn Y Ang; Nahed Abdel-Haq; Frank Zhu; Abrar K Thabit; David P Nicolau; Michael J Satlin; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  MIC score, a new tool to compare bacterial susceptibility to antibiotics application to the comparison of susceptibility to different penems of clinical strains of Pseudomonas aeruginosa.

Authors:  Cédric Bretonnière; Adeline Maitte; Jocelyne Caillon; Gilles Potel; David Boutoille; Cédric Jacqueline; Christophe Guitton
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

7.  Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.

Authors:  Seetha M Tamma; Alice J Hsu; Pranita D Tamma
Journal:  Paediatr Drugs       Date:  2016-02       Impact factor: 3.022

8.  In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Dale M Mazer; Carol Young; Linda M Kalikin; Theodore Spilker; John J LiPuma
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

9.  Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.

Authors:  Hana Rac; Kayla R Stover; Jamie L Wagner; S Travis King; Henderson D Warnock; Katie E Barber
Journal:  Infect Dis Ther       Date:  2017-10-20

10.  In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients.

Authors:  Aimee M Dassner; Christina Sutherland; Jennifer Girotto; David P Nicolau
Journal:  Infect Dis Ther       Date:  2016-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.